

RESEARCH MONOGRAPH . COMPOUND PROFILE

Lisuride

A semisynthetic ergot alkaloid dopamine agonist distinguished from other ergolines by 5-HT_{2B} receptor antagonism (conferring absence of cardiac valvulopathy risk), G protein-biased 5-HT_{2A} partial agonism without hallucinogenic activity, and broad translational applications spanning Parkinson's disease, hyperprolactinemia, migraine prophylaxis, and emerging antidepressant research.

DOCUMENT	KDC-MN-1590
ISSUED	2026-05-20
REVISION	1.0
AUTHOR	Kodiak bioLabs Research
COMPOUND CLASS	Semisynthetic 8- α -ergoline dopamine D ₂ /D ₃ receptor agonist with multimodal serotonergic, adrenergic, and histaminergic activity

ABSTRACT

Lisuride (1,1-diethyl-3-[(8- α)-6-methyl-9,10-didehydroergolin-8-yl]urea) is a semisynthetic 8- α -ergoline derivative first synthesized by Zikan and Semonsky at the Research Institute for Pharmacy and Biochemistry in Prague in 1960 as an antimigraine agent analogous to methysergide. It was subsequently developed by Schering AG (Berlin) as a dopamine D2/D3 receptor agonist for the treatment of Parkinson's disease, hyperprolactinemia, and migraine prophylaxis, and has been marketed in multiple European, Asian, and Latin American jurisdictions under the brand names Dopergin, Cuvalit, Lysenyl, Revanil, and others. Lisuride is the most potent of the classical ergoline dopamine agonists by receptor binding affinity, with sub-nanomolar K_i values at the dopamine D2 and D3 receptors and the serotonin 5-HT1A receptor, and low-nanomolar affinity across a broad panel of monoamine targets including dopamine D1, D4, and D5 receptors, serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, α -1 and α -2 adrenergic receptors, and the histamine H1 receptor. This broad receptor engagement, sometimes characterized as "dirty drug" pharmacology, produces a clinically diverse profile that distinguishes lisuride from both the older ergoline bromocriptine and the newer non-ergoline dopamine agonists ropinirole and pramipexole.

Two pharmacological features of lisuride have attracted particular research interest in the 2020s. First, lisuride is a silent antagonist at the serotonin 5-HT2B receptor, in contrast to the ergoline dopamine agonists pergolide and cabergoline, which are 5-HT2B agonists. Because 5-HT2B receptor agonism on cardiac valvular

interstitial cells is the established molecular mechanism of the fibrotic cardiac valvulopathy that led to the withdrawal of pergolide and the black-box labeling of cabergoline, the 5-HT_{2B} antagonist profile of lisuride is associated with the absence of cardiac valvulopathy adverse drug reaction reports in pharmacovigilance databases, supporting the concept that 5-HT_{2B} agonism (not ergoline structure per se) is the critical determinant of fibrotic risk [1]. Second, lisuride is a G protein-biased partial agonist at the serotonin 5-HT_{2A} receptor: it activates 5-HT_{2A}-mediated Gq/11 signaling without recruiting beta-arrestin 2, and in consequence does not produce the head-twitch response in rodents or hallucinogenic activity in humans that characterizes the structurally related lysergic acid diethylamide (LSD) and other beta-arrestin-biased 5-HT_{2A} agonists [2, 3]. This biased signaling profile has positioned lisuride as a key pharmacological tool for dissecting the signaling pathways responsible for psychedelic versus therapeutic 5-HT_{2A} receptor effects, and recent preclinical evidence demonstrates that lisuride exerts antidepressant-like and psychoplastogenic effects in mice through G protein-dependent mechanisms without hallucinogenic activity [3].

Pharmacokinetics of oral lisuride are characterized by complete gastrointestinal absorption, high first-pass hepatic metabolism reducing absolute oral bioavailability to 10 to 20 percent, peak plasma concentrations at 60 to 80 minutes, a short elimination half-life of approximately 2 hours, and plasma protein binding of 60 to 70 percent [4]. More than 15 metabolites have been identified. The short half-life motivated the development of continuous subcutaneous infusion protocols for advanced Parkinson's disease with motor fluctuations (lisuride was the first dopamine agonist used for chronic subcutaneous pump delivery)

and transdermal patch formulations intended to provide sustained plasma concentrations and continuous dopaminergic stimulation [5, 6]. Clinical evidence in Parkinson's disease demonstrates that continuous subcutaneous lisuride infusion significantly reduces off-time and dyskinesia compared to oral levodopa, with sustained benefit over four years in prospective randomized trials [7]. Oral lisuride at doses of 0.6 to 5 mg daily has demonstrated comparable antiparkinsonian efficacy to bromocriptine in adjunctive therapy, though firm conclusions on oral efficacy are limited by the absence of large randomized controlled trials [8, 9]. The compound is well tolerated at clinical doses; the principal adverse events are nausea, dizziness, orthostatic hypotension, and psychiatric effects (hallucinations, confusion) at higher doses, consistent with the dopamine agonist class. The absence of cardiac valvulopathy signal distinguishes the safety profile from pergolide and cabergoline. This monograph reviews the chemistry, synthesis, and receptor pharmacology of lisuride; the comprehensive pharmacokinetic record across oral, subcutaneous, and transdermal routes; the clinical evidence base across Parkinson's disease, hyperprolactinemia, migraine, and emerging antidepressant indications; sourcing, reconstitution, and stack-interaction considerations; adverse-event signal and safety; and a comparative assessment of five dopamine agonist alternatives against lisuride on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Lisuride.

Marketed names: Dopergin (Schering AG; Germany, several European markets), Cuvalit (Germany), Lysenyl (multiple markets), Revanil, Proclacam, Prolacam, Arolac, Dopagone, Doperpine, Eunal, Lisenil, Lizenil.

Development codes: The compound was originally synthesized without a formal development code designation; it is identified in the early Czech pharmacological literature by the systematic chemical name and by the Zikan-Semonsky reference [10].

Chemical Abstracts Service registry numbers: 18016-80-3 (free base), 19875-60-6 (hydrogen maleate salt). The free base is the synthetic and reference form; the hydrogen maleate salt is the standard pharmaceutical formulation for oral and parenteral preparations.

International Union of Pure and Applied Chemistry name: 3-[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea. An alternative systematic name used in older literature is 1,1-diethyl-3-(6-methyl-9,10-didehydroergolin-8- α -yl)urea.

PubChem CID: 28864.

1.2 Structural class and chemistry

Lisuride is a semisynthetic 8- α -ergoline, a subclass of the ergot alkaloid family. The ergoline tetracyclic ring system (indolo[4,3-fg]quinoline) is shared with lysergic acid, ergotamine, bromocriptine, pergolide, cabergoline, and other medicinally important ergolines. Lisuride is distinguished from lysergic acid amides by the presence of a 1,1-diethylurea substituent at the C-8 position (replacing the carboxamide of LSD or the peptide chain of ergotamine) and by the 9,10-didehydro unsaturation that confers the D-ring conjugation characteristic of the lysergic acid series [10].

Molecular formula: C₂₀H₂₆N₄O (free base); C₂₄H₃₀N₄O₅ (hydrogen maleate salt).

Exact mass: 338.211 g/mol (free base, monoisotopic).

Molecular weight: 338.45 g/mol (free base); 454.52 g/mol (hydrogen maleate salt).

Physical properties: White to slightly yellowish crystalline powder. Soluble in dimethyl sulfoxide and in acidified aqueous solutions; sparingly soluble in water at neutral pH. The hydrogen maleate salt has improved aqueous solubility suitable for parenteral formulation. Melting point of the free base is approximately 198 to 202 degrees Celsius.

Stereochemistry: Lisuride contains two stereocenters at C-6a (corresponding to C-5 in the older numbering) and C-9 (corresponding to C-8 in older convention) of the ergoline ring system. The natural ergoline configuration is (6aR,9S), also designated 8- α . This stereochemistry is critical for dopamine receptor binding; the 8- β epimer is substantially less active. Commercial material is supplied exclusively as the (6aR,9S) enantiomer.

1.3 Synthesis

The original synthesis of lisuride was reported by Zikan and Semonsky in 1960 [10]. The procedure involves conversion of lysergic acid hydrazide (obtained from lysergic acid, itself derived from ergot alkaloid fermentation or total synthesis) to the corresponding isocyanate or activated carbamate intermediate, followed by reaction with diethylamine to form the 1,1-diethylurea side chain at the C-8 position. Alternative routes proceed through direct coupling of lysergic acid with 1,1-diethylurea using carbodiimide-mediated amidation or through Curtius rearrangement of the lysergic acid azide followed by trapping with diethylamine. The 9,10-double bond is preserved throughout the synthesis. Purification is achieved by column chromatography and recrystallization. The hydrogen maleate salt is prepared by treatment of the free base with maleic acid in an appropriate solvent (typically ethanol or acetone) followed by recrystallization. Industrial synthesis relies on semisynthetic routes from lysergic acid obtained by fermentation of *Claviceps purpurea* or from total synthetic lysergic acid; the compound is manufactured in moderate to large scale for European pharmaceutical markets.

2. Abstract

Lisuride is a semisynthetic 8- α -ergoline derivative with potent dopamine D2/D3 receptor agonist activity and a broad multimodal pharmacological profile encompassing serotonergic, adrenergic, and histaminergic receptor interactions. Synthesized in 1960 by Zikan and Semonsky in Prague as an antimigraine agent, lisuride was subsequently developed by Schering AG (Berlin) for the treatment of Parkinson's disease, hyperprolactinemia, and migraine prophylaxis, receiving marketing authorization in multiple European and other jurisdictions beginning in the early 1970s [10, 11].

The pharmacological profile of lisuride is characterized by sub-nanomolar affinity at the dopamine D2, D3, serotonin 5-HT1A, and 5-HT1D receptors, and low-nanomolar affinity across a broad panel including D1, D4, D5, 5-HT2A, 5-HT2B, 5-HT2C, α -1 and α -2 adrenergic, and histamine H1 receptors. Functionally, lisuride is a partial agonist at D2, D3, D4, 5-HT2A, 5-HT2C, 5-HT5A, and H1 receptors; a full agonist at 5-HT1A, 5-HT1B, and 5-HT1D receptors; and a silent antagonist at the 5-HT2B receptor and at α -1 and α -2 adrenergic receptors [12, 13]. This multi-target profile accounts for the compound's diverse clinical applications and distinguishes it from both the older ergoline bromocriptine (which has lower D2 affinity and partial D1 agonism) and the non-ergoline agonists ropinirole and pramipexole (which are selective for D2/D3 without serotonergic or adrenergic activity).

Two features of the lisuride receptor profile have generated substantial contemporary research interest. The 5-HT2B antagonism distinguishes lisuride from the ergolines pergolide and cabergoline, whose 5-HT2B agonism mediates the fibrotic cardiac valvulopathy that led to regulatory action against those agents; pharmacovigilance databases contain no cardiac valvulopathy reports for lisuride, supporting the hypothesis that 5-HT2B agonism rather than the ergoline scaffold is the critical risk determinant [1]. The G protein-biased partial agonism at the 5-HT2A receptor explains the long-standing observation that lisuride, despite high 5-HT2A affinity comparable to LSD, does not produce hallucinogenic effects in humans or head-twitch responses in rodents; lisuride activates Gq/11 signaling without recruiting β -arrestin 2, whereas LSD and classical psychedelics are β -arrestin-biased at the same receptor [2, 3]. This biased signaling profile has made lisuride a

central pharmacological tool for dissecting psychedelic versus non-psychedelic 5-HT_{2A} receptor signaling, and recent work has demonstrated antidepressant-like and psychoplastogenic activity in mouse models through the G protein-dependent pathway [3].

Clinical applications of lisuride span Parkinson's disease (both oral adjunctive therapy and continuous subcutaneous infusion for motor fluctuations), hyperprolactinemia (suppression of prolactin secretion with restoration of fertility and gonadal function), and migraine prophylaxis (at microgram-range oral doses as a peripheral serotonin antagonist). The compound was the first dopamine agonist to be administered by chronic subcutaneous pump infusion for advanced Parkinson's disease, a delivery innovation that demonstrated sustained reduction of motor fluctuations and dyskinesia over four years in prospective comparison with oral levodopa [5, 7]. Transdermal patch formulations have been evaluated in Phase 2 clinical trials for Parkinson's disease with the goal of achieving continuous dopaminergic stimulation through sustained transdermal delivery [6].

Pharmacokinetics are characterized by complete gastrointestinal absorption, extensive first-pass hepatic metabolism reducing oral bioavailability to 10 to 20 percent, peak plasma concentration at 60 to 80 minutes after oral dosing, a short elimination half-life of approximately 2 hours, and plasma protein binding of 60 to 70 percent. Parenteral routes (subcutaneous, intramuscular) achieve systemic bioavailability exceeding 90 percent. More than 15 metabolites have been identified; the specific cytochrome P450 isoforms involved in metabolism have not been fully characterized in the published literature.

This monograph reviews the chemistry, stereochemistry, and synthesis of lisuride; the multimodal receptor pharmacology in molecular detail; the pharmacokinetic profile across oral, subcutaneous, and transdermal routes; the clinical evidence base in Parkinson's disease, hyperprolactinemia, migraine, and emerging antidepressant research; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal and safety; and a comparative assessment of five dopamine agonist alternatives (bromocriptine, pergolide, cabergoline, ropinirole, pramipexole) against lisuride on five competency standards.

3. Discovery and Development History

3.1 Origin

Lisuride was synthesized in 1960 by Vojtech Zikan and Milan Semonsky at the Research Institute for Pharmacy and Biochemistry (VUFRB) in Prague, Czechoslovakia, as part of a medicinal chemistry program exploring ergoline derivatives for antimigraine applications analogous to the then-recently introduced methysergide [10]. The design rationale was to produce an ergoline with potent peripheral serotonin antagonist activity suitable for migraine prophylaxis while minimizing the vasoconstrictor properties of ergotamine and the fibrotic complications emerging from chronic methysergide use. The 1,1-diethylurea substituent at the C-8 position was selected on the basis of structure-activity studies of lysergic acid amide and hydrazide derivatives.

3.2 Early clinical development as antimigraine agent

Initial clinical evaluation in the 1960s confirmed that lisuride at oral doses of 0.025 mg three times daily was an effective migraine prophylactic agent, comparable to methysergide in reduction of attack frequency and severity. This led to registration by Schering AG (West Berlin) as a peripheral serotonin antagonist for migraine prevention in the Federal Republic of Germany and subsequently in other European markets. The microgram-range dosing for migraine reflects the high receptor affinity of the compound and established the first marketed indication [11].

3.3 Identification of dopaminergic activity and Parkinson's disease development

In the mid-1970s, the dopamine receptor agonist properties of lisuride were characterized by Horowski and colleagues at Schering AG, who demonstrated that lisuride was a potent direct-acting postsynaptic dopamine receptor agonist with antiparkinsonian activity in animal models [14, 15]. This discovery repositioned lisuride from a peripheral serotonin antagonist to a central dopamine agonist and launched a clinical development program for Parkinson's disease. Phase 1 and Phase 2 trials in the late 1970s demonstrated significant improvements in bradykinesia, rigidity, gait

disorders, and overall parkinsonian symptoms, both as monotherapy and as adjunctive therapy to levodopa. Marketing authorization for the Parkinson's disease indication was obtained in Germany and other European jurisdictions under the brand name Dopergin, with recommended oral doses of 0.6 to 5 mg daily in divided doses [8].

3.4 Hyperprolactinemia indication

Clinical studies in the early 1980s demonstrated that lisuride, through its D2 receptor agonist activity on pituitary lactotrophs, was an effective suppressor of prolactin secretion. At oral doses of 0.2 to 0.6 mg daily, lisuride restored ovulatory menses in women with tumoral and idiopathic hyperprolactinemia and improved sexual function in men with prolactin-secreting adenomas. The compound was registered for this indication in several European markets [16, 17].

3.5 Subcutaneous infusion innovation

In the mid-1980s, lisuride became the first dopamine agonist administered by chronic subcutaneous pump infusion for the management of motor fluctuations in advanced Parkinson's disease. The rationale was that continuous dopaminergic stimulation, avoiding the pulsatile receptor stimulation associated with oral levodopa, would reduce the amplitude and frequency of on-off fluctuations and peak-dose dyskinesia. Obeso and colleagues demonstrated the feasibility and efficacy of subcutaneous lisuride infusion via portable minipump in 1986, establishing a treatment paradigm later adopted with apomorphine [5, 18]. Long-term prospective studies confirmed sustained benefit over multiple years [7].

3.6 Transdermal patch development

Transdermal delivery of lisuride was explored beginning in the early 2000s as a means of achieving continuous dopaminergic stimulation without the burden of a subcutaneous pump. A Phase 2 clinical trial (NCT00089622) sponsored by the National Institute of Neurological Disorders and Stroke (NINDS) evaluated a lisuride transdermal patch for Parkinson's disease [6]. The CALIPSO study (NCT00408915) evaluated subcutaneous lisuride by minipump in advanced Parkinson's disease patients refractory to oral therapy. These approaches reflect the continued clinical interest in lisuride's pharmacology despite the commercial dominance of the non-ergoline dopamine agonists.

3.7 Contemporary research: biased 5-HT_{2A} signaling and antidepressant activity

Beginning approximately 2005 with the seminal work of Gonzalez-Maeso and colleagues, lisuride was identified as a key pharmacological probe for biased agonism at the 5-HT_{2A} receptor [2]. The demonstration that lisuride and LSD, despite similar binding affinities and overlapping receptor profiles, produce fundamentally different behavioral and signaling outcomes (lisuride activating G protein signaling without beta-arrestin recruitment; LSD recruiting beta-arrestin and producing hallucinations) established a major paradigm in receptor pharmacology. In 2023, Secker and colleagues demonstrated that lisuride exerts antidepressant-like effects in mouse models (forced swim test, tail suspension test, novelty-suppressed feeding) through G protein-biased 5-HT_{2A} signaling, with psychoplastogenic effects (increased dendritic spine density) comparable to those of classical psychedelics but without hallucinogenic-like behavior [3]. This work has positioned lisuride at the center of contemporary research into non-hallucinogenic psychoplastogens as potential rapid-acting antidepressants.

4. Mechanism of Action

Lisuride is a multi-target ergoline ligand. Its principal molecular activities, characterized in heterologous expression systems and confirmed in native tissue and behavioral models, encompass agonism at dopamine D2-family receptors, full agonism at serotonin 5-HT_{1A/1B/1D} receptors, G protein-biased partial agonism at serotonin 5-HT_{2A} receptors, antagonism at serotonin 5-HT_{2B} receptors, and antagonism at adrenergic receptors. These activities operate at functionally relevant concentrations achieved by clinical dosing and contribute differentially to the observed antiparkinsonian, prolactin-suppressing, antimigraine, and emerging antidepressant effects.

4.1 Dopamine receptor agonism

Lisuride binds the dopamine D₂ receptor with sub-nanomolar affinity (K_i approximately 0.2 to 0.9 nM depending on species and assay), making it the most potent of the classical ergoline dopamine agonists by this metric [12, 13]. At the D₃ receptor, affinity is similarly sub-nanomolar. At D₁, D₄, and D₅ receptors, affinity is in the low-nanomolar range (K_i approximately 2 to 20 nM). Functionally, lisuride is a partial agonist at D₂, D₃, and D₄ receptors, with intrinsic activity of approximately 50 to 80 percent of the maximal dopamine response depending on the assay system and receptor density [12]. At the D₁ receptor, lisuride shows no apparent agonist activity, functioning as a silent ligand or weak antagonist. This D₂-selective agonist/D₁-inactive profile contrasts with bromocriptine, which has weak D₁ agonist activity, and with the non-ergoline agonists ropinirole and pramipexole, which are D₂/D₃-selective but lack the broad serotonergic and adrenergic interactions of lisuride.

The therapeutic consequences of D₂ receptor agonism include: (a) stimulation of postsynaptic D₂ receptors in the striatum, producing antiparkinsonian effects by compensating for the dopamine deficit of the nigrostriatal pathway; (b) stimulation of D₂ receptors on pituitary lactotroph cells, inhibiting prolactin release through the same transduction pathway (G_i-mediated inhibition of adenylyl cyclase); and

(c) stimulation of presynaptic D2 autoreceptors at lower doses, reducing dopamine synthesis and release (the basis of the low-dose anxiolytic and antidepressant research literature).

4.2 Serotonin receptor pharmacology

The serotonergic profile of lisuride is complex and functionally heterogeneous across receptor subtypes.

5-HT_{1A} receptor: Lisuride is a full agonist with sub-nanomolar affinity (K_i approximately 0.2 to 0.3 nM) [12, 13]. This exceptionally high 5-HT_{1A} affinity contributes to anxiolytic and antidepressant activity through somatodendritic 5-HT_{1A} autoreceptor-mediated modulation of serotonergic firing and through postsynaptic 5-HT_{1A} receptor activation in hippocampus and prefrontal cortex.

5-HT_{1B} and 5-HT_{1D} receptors: Full agonism at sub-nanomolar to low-nanomolar affinity. The 5-HT_{1B/1D} agonist activity contributes to the antimigraine mechanism (vasoconstriction of dilated cranial arteries and inhibition of trigeminal nociceptive transmission), paralleling the mechanism of the triptan antimigraine class.

5-HT_{2A} receptor: Partial agonism at low-nanomolar affinity (K_i approximately 2 to 9 nM) [12, 13]. The 5-HT_{2A} interaction is the subject of the most active contemporary research on lisuride. Lisuride activates 5-HT_{2A}-coupled Gq/11 signaling (phospholipase C activation, inositol trisphosphate production, intracellular calcium mobilization) but does not recruit beta-arrestin 2 to the receptor complex [2]. This G protein-biased signaling pattern is the molecular basis for the non-hallucinogenic pharmacology of lisuride despite its high 5-HT_{2A} affinity. In contrast, LSD, psilocybin, and other classical psychedelics recruit beta-arrestin 2 at the 5-HT_{2A} receptor, and the beta-arrestin-dependent signaling cascade (including activation of intracellular kinase pathways distinct from the G protein cascade) is hypothesized to be necessary for the subjective hallucinogenic experience [2, 19].

The Gonzalez-Maeso et al. (2007) study in mice demonstrated that lisuride and LSD, administered at equi-affinity doses, produce overlapping patterns of cortical gene expression through 5-HT_{2A} receptor activation, but LSD (and not lisuride) induces the head-twitch response (a behavioral correlate of hallucinogenic activity in rodents) and activates a specific subset of genes through the beta-arrestin-dependent pathway [2]. The Secker et al. (2023) study extended this by demonstrating that lisuride produces antidepressant-like behavioral effects and increases dendritic

spine density (psychoplastogenesis) through G protein-dependent 5-HT_{2A} signaling, effects that do not require beta-arrestin 1 or 2, as demonstrated in beta-arrestin knockout mouse models [3].

5-HT_{2B} receptor: Silent antagonism at low-nanomolar affinity (K_i approximately 1 to 3 nM) [1, 12]. This is the pharmacological feature most relevant to the cardiac safety differentiation of lisuride from pergolide and cabergoline. The 5-HT_{2B} receptor is expressed on cardiac valvular interstitial cells, and agonist activation drives proliferation and collagen deposition, producing the fibrotic valvulopathy observed with chronic pergolide and cabergoline exposure. Lisuride, by antagonizing 5-HT_{2B}, does not activate this fibrotic pathway and may actively oppose it. Hofmann et al. (2006) analyzed pharmacovigilance databases and confirmed the complete absence of cardiac valvulopathy adverse drug reaction reports for lisuride, providing clinical-epidemiological support for the mechanistic hypothesis [1].

5-HT_{2C} receptor: Partial agonism at low-nanomolar affinity. The 5-HT_{2C} interaction may contribute to appetite-modulating effects and to the complex psychiatric profile at higher doses.

5-HT_{5A} receptor: Partial agonism. The functional significance of this interaction is poorly characterized.

4.3 Adrenergic and histaminergic receptor pharmacology

Lisuride is a silent antagonist at alpha-1A, alpha-1B, alpha-1D, alpha-2A, alpha-2B, and alpha-2C adrenergic receptors, with sub-nanomolar to low-nanomolar affinity [12, 13]. The alpha-1 antagonism contributes to orthostatic hypotension (the principal cardiovascular adverse event), while alpha-2 antagonism may modulate norenergic neurotransmission. At the histamine H₁ receptor, lisuride is a low-affinity partial agonist; the clinical significance of this interaction is minor relative to the dominant dopaminergic and serotonergic mechanisms.

4.4 Composite pharmacology and clinical implications

The composite receptor profile of lisuride at clinical oral doses (0.2 to 5 mg daily, producing peak plasma concentrations in the low-nanomolar range) predicts near-complete occupancy of D₂, D₃, 5-HT_{1A}, and 5-HT_{1D} receptors; substantial occupancy of 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C}, and adrenergic receptors; and the functionally heterogeneous responses (agonism, partial agonism, antagonism) at each target.

The multi-target mechanism explains both the breadth of clinical indications and the "dirty drug" characterization. From a contemporary pharmacological perspective, the polypharmacology of lisuride may be an advantage rather than a liability: the simultaneous D2 agonism, 5-HT1A agonism, 5-HT2A G protein-biased partial agonism, and 5-HT2B antagonism constitute a pharmacological profile that no single-target agent recapitulates, and one that is increasingly recognized as potentially optimal for combined neuropsychiatric benefit with cardiac safety.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Lisuride is completely absorbed from the gastrointestinal tract after oral administration. However, extensive first-pass hepatic metabolism reduces the absolute oral bioavailability to approximately 10 to 20 percent, with substantial inter-individual variability [4]. Peak plasma concentration after oral administration of lisuride hydrogen maleate occurs at approximately 60 to 80 minutes. Food effects on absorption have not been formally characterized in published studies but are considered modest on the basis of clinical experience with the marketed oral formulations.

After subcutaneous injection, systemic bioavailability is approximately 94 percent, with peak plasma concentration at 12 to 15 minutes. After intramuscular injection, bioavailability is approximately 90 percent with similar time to peak [4]. The high parenteral bioavailability relative to oral delivery reflects bypass of first-pass hepatic metabolism and is the pharmacokinetic basis for the subcutaneous infusion paradigm in advanced Parkinson's disease.

5.2 Distribution

Plasma protein binding is approximately 60 to 70 percent. The volume of distribution has not been precisely reported in the published human pharmacokinetic literature but is estimated to be moderate to large on the basis of the compound's lipophilicity and tissue distribution. Lisuride crosses the blood-brain barrier; central nervous system penetration is supported by the demonstrated central pharmacological effects (antiparkinsonian, prolactin-suppressive, and behavioral actions) at clinically achieved plasma concentrations.

5.3 Metabolism

Lisuride undergoes extensive hepatic metabolism, producing more than 15 identified metabolites. The metabolic transformations include N-demethylation, oxidation of the ergoline ring system, hydrolysis of the urea side chain, and conjugation

reactions. The specific cytochrome P450 isoforms responsible for lisuride metabolism have not been fully characterized in the published literature. Some evidence suggests involvement of CYP3A4 based on structural analogy with other ergolines metabolized by this isoform, but definitive isoform identification studies (such as those conducted for bromocriptine and cabergoline) have not been published for lisuride.

5.4 Elimination

After intravenous administration, plasma lisuride concentrations decline in a biphasic pattern with distribution half-life of approximately 14 minutes and terminal elimination half-life of approximately 1.5 to 2 hours [4]. The short half-life necessitates multiple daily oral dosing (typically three to four times daily for the Parkinson's disease indication) and was the primary driver for the development of continuous subcutaneous infusion and transdermal patch delivery systems.

Total clearance after intravenous administration is approximately 13 mL/min/kg, indicating high hepatic extraction [4]. Renal excretion of unchanged lisuride is minimal; the compound is eliminated predominantly through hepatic biotransformation and biliary excretion of metabolites.

5.5 Routes of administration

Oral: The standard route for Parkinson's disease, hyperprolactinemia, and migraine prophylaxis. Oral doses for Parkinson's disease range from 0.6 to 5 mg daily in divided doses (typically three to four times daily). For migraine prophylaxis, the dose is much lower: 0.025 mg (25 micrograms) three times daily. For hyperprolactinemia, typical doses are 0.2 to 0.6 mg daily [8, 16].

Subcutaneous infusion: Continuous delivery via portable minipump for advanced Parkinson's disease with motor fluctuations. Typical infusion rates are 0.1 to 0.5 mg/hour, adjusted to clinical response. This route was pioneered by Obeso and colleagues in the mid-1980s and predates the apomorphine subcutaneous infusion paradigm [5, 18].

Subcutaneous and intramuscular injection: Bolus parenteral administration for acute dosing or pharmacokinetic studies. Bioavailability exceeds 90 percent by either route [4].

Transdermal: Patch formulations evaluated in Phase 2 trials for Parkinson's disease. The transdermal route aims to achieve steady-state plasma concentrations that provide continuous dopaminergic stimulation without the pulsatile pharmacokinetics of oral dosing or the invasiveness of subcutaneous pump delivery [6].

Intravenous: Used in pharmacokinetic studies and in some clinical research protocols. Intravenous administration produces immediate peak plasma concentrations followed by rapid biphasic decline.

5.6 Special populations

Pediatric pharmacokinetics have not been formally characterized; the compound is not indicated for pediatric use. Geriatric pharmacokinetics are similar to adult values, though the elderly may be more susceptible to orthostatic hypotension and psychiatric adverse events. Hepatic impairment is expected to increase systemic exposure owing to the high hepatic extraction; dose reduction is appropriate. Renal impairment has minimal impact on exposure given the hepatic clearance pathway. Pregnancy data are limited; the compound suppresses prolactin and is contraindicated in patients desiring maintenance of pregnancy.

6. Clinical Evidence Base

6.1 Parkinson's disease: oral adjunctive therapy

The principal clinical application of oral lisuride in Parkinson's disease is as adjunctive therapy to levodopa in patients experiencing motor fluctuations. Open-label studies in the early 1980s demonstrated that oral lisuride at doses of 0.6 to 5 mg daily reduced off-time and smoothed motor fluctuations when added to levodopa therapy [8, 9]. A mean optimal daily dose of 4.5 mg was reported in one series of 28 patients, with some requiring up to 10 mg; eleven patients continued lisuride for more than one year with sustained benefit [8].

Only one randomized controlled trial has directly compared oral lisuride with bromocriptine as adjunctive therapy: a crossover trial in 20 patients demonstrated that both agents improved motor fluctuations with no significant difference between them, though the trial used an unvalidated 4-point rating scale and was underpowered for definitive conclusions [9, 20]. A Cochrane systematic review concluded that while open-label evidence supports lisuride's capacity to reduce off-time, no evidence from adequately powered randomized controlled trials is available to definitively establish the efficacy and safety of oral lisuride in later Parkinson's disease [20].

6.2 Parkinson's disease: continuous subcutaneous infusion

The most compelling clinical evidence for lisuride in Parkinson's disease comes from the subcutaneous infusion literature. A prospective randomized trial by Stocchi and colleagues (2002) compared continuous subcutaneous lisuride infusion with standard oral levodopa therapy in patients with advanced Parkinson's disease and motor fluctuations [7]. The principal findings were: (a) patients receiving lisuride infusion had significantly reduced daily off-time compared to those receiving oral levodopa; (b) dyskinesia severity was significantly reduced in the lisuride infusion group; (c) Unified Parkinson's Disease Rating Scale (UPDRS) scores in on and off states did not significantly change from baseline over four years in the lisuride group, whereas they deteriorated in the levodopa group; and (d) oral levodopa dose could be substantially reduced in the lisuride infusion group.

Earlier studies by Obeso et al. (1986, 1988) demonstrated the feasibility of chronic subcutaneous lisuride infusion and reported highly effective control of motor fluctuations in patients refractory to oral therapy [5, 18]. Vaamonde et al. (1991) reported subcutaneous lisuride infusion outcomes in 34 patients, confirming sustained reduction of fluctuations but noting psychiatric complications (hallucinations, paranoid ideation) in a minority of patients at higher doses [21].

The CALIPSO study (NCT00408915) was a Phase 2/3 trial evaluating subcutaneous lisuride by minipump in advanced Parkinson's disease patients refractory to conventional oral therapy. Results from this trial have not been published in a peer-reviewed journal as of the most recent revision of this monograph.

6.3 Parkinson's disease: transdermal delivery

A Phase 2 trial (NCT00089622) sponsored by NINDS evaluated a lisuride transdermal patch for Parkinson's disease [6]. The concept was to achieve continuous dopaminergic stimulation through sustained transdermal delivery, avoiding both the pulsatile oral pharmacokinetics and the invasiveness of subcutaneous pump therapy. Published results from this trial are limited; the transdermal lisuride program did not advance to Phase 3 registration trials.

6.4 Hyperprolactinemia

Lisuride at oral doses of 0.2 to 0.6 mg daily is an effective suppressor of prolactin secretion through D2 receptor agonist activity on pituitary lactotrophs. Clinical studies in the 1980s demonstrated that lisuride reduced serum prolactin levels, restored ovulatory menstrual cycles in women with tumoral and idiopathic hyperprolactinemia, induced shrinkage of prolactin-secreting macroadenomas, and improved sexual function in men with hyperprolactinemia [16, 17]. The compound was registered for this indication in several European markets. Comparative data with bromocriptine suggest broadly similar efficacy for prolactin suppression, with lisuride potentially better tolerated at equivalent efficacy owing to lower gastrointestinal adverse-event rates in some studies. Cabergoline subsequently displaced both lisuride and bromocriptine for hyperprolactinemia in most markets owing to its longer half-life (permitting once or twice weekly dosing) and superior tolerability.

6.5 Migraine prophylaxis

The original indication for lisuride was migraine prophylaxis, at oral doses of 0.025 mg three times daily. At this microgram-range dose, the principal mechanism is peripheral serotonin (5-HT₂) antagonism, analogous to methysergide. Clinical trials in the 1970s and 1980s demonstrated efficacy in reducing migraine frequency and severity, comparable to methysergide but with a potentially more favorable safety profile (particularly regarding retroperitoneal and pleuropulmonary fibrosis, which were associated with chronic methysergide use) [11]. The migraine indication has been largely superseded by the triptan class for acute treatment and by valproate, topiramate, propranolol, and more recently the CGRP monoclonal antibodies for prophylaxis.

6.6 Emerging research: antidepressant and psychoplastogenic activity

The most active contemporary research application of lisuride is in the investigation of non-hallucinogenic 5-HT_{2A} receptor agonists as potential rapid-acting antidepressants. The Secker et al. (2023) study demonstrated that lisuride produces antidepressant-like behavioral responses in multiple mouse models (forced swim test, tail suspension test, novelty-suppressed feeding) with onset and magnitude comparable to those of psilocybin, and induces dendritic spine growth (psychoplastogenesis) in prefrontal cortex consistent with the structural plasticity effects of psychedelic compounds [3]. Critically, these effects occurred without hallucinogenic-like behavior (no head-twitch response) and were preserved in beta-arrestin 1 and beta-arrestin 2 knockout mice, confirming the G protein-biased mechanism. A 2025 review by Kehler and Thomsen Lindskov examined whether lisuride and the related ergoline ergotamine represent examples of non-hallucinogenic 5-HT_{2A} receptor agonists with therapeutic potential [19].

No human clinical trials of lisuride for depression have been published as of the current revision. The preclinical data provide a mechanistic rationale for clinical investigation, and the established human safety database at clinical doses provides a regulatory pathway for investigator-initiated trials.

6.7 Other investigated indications

Lisuride has been investigated for alcohol dependence (one controlled trial of lisuride as an anticraving agent in alcohol-dependent patients, with mixed results), acromegaly (limited data), and cluster headache. None of these indications has produced registration-quality evidence.

7. Reported Research Dose Ranges

7.1 Approved doses

Parkinson's disease (oral): 0.1 to 0.2 mg initially, titrated to 0.6 to 5 mg daily in three to four divided doses. Some patients require up to 10 mg daily [8].

Hyperprolactinemia (oral): 0.2 to 0.6 mg daily in divided doses.

Migraine prophylaxis (oral): 0.025 mg (25 micrograms) three times daily.

7.2 Investigational doses

Subcutaneous infusion (Parkinson's disease): 0.1 to 0.5 mg/hour continuous infusion via portable minipump, adjusted to clinical response. Total daily doses of 2 to 12 mg have been reported [5, 7].

Transdermal (Parkinson's disease): Patch doses evaluated in Phase 2 trials; specific dose parameters are not fully published.

Prolactin suppression pharmacodynamic studies: Intravenous bolus of 50 to 200 micrograms; subcutaneous bolus of 100 to 500 micrograms. Prolactin concentrations reduced by approximately 60 percent relative to circadian baseline [4].

Investigators acquiring research-grade lisuride should be aware of the high potency of the compound and the microgram-range doses effective for some indications. Dose ranges should be treated as starting points, with titration guided by pharmacokinetic and pharmacodynamic response.

8. Sourcing and Quality Verification

Research-grade lisuride (free base or hydrogen maleate salt) is available from multiple chemical and pharmaceutical research suppliers (Sigma-Aldrich, Tocris, Cayman Chemical, MedChemExpress, Santa Cruz Biotechnology, MuseChem, others) at greater than 98 percent purity by HPLC. The free base (CAS 18016-80-3) and the hydrogen maleate salt (CAS 19875-60-6) are both commercially available in milligram to gram quantities.

Pharmaceutical-grade lisuride (Dopergin brand or licensed generic) is available in jurisdictions where the compound is registered (principally Germany and other European markets). Pharmaceutical presentations include 0.2 mg and 0.5 mg oral tablets and injectable formulations.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (339.218 for the protonated free base $[M+H]^+$, or 455.228 for the protonated hydrogen maleate $[M+H]^+$)
- Nuclear magnetic resonance spectroscopy (1H and ^{13}C) for structural confirmation, especially confirmation of the ergoline ring system and the 1,1-diethylurea side chain
- Chiral HPLC or optical rotation measurement to confirm the (6aR,9S) stereochemistry, as the 8-beta epimer has substantially reduced pharmacological activity
- Residual solvent analysis for common synthesis solvents

The research-grade ergoline market is moderately established; lot-to-lot variability and the presence of ergoline-related impurities (lysergic acid derivatives, oxidation products) warrant analytical confirmation for any investigation where dose-response precision is important.

9. Reconstitution and Handling

Lisuride free base has limited aqueous solubility at neutral pH. For in vitro research, stock solutions are typically prepared in dimethyl sulfoxide (DMSO) at 10 to 50 mM concentration, with subsequent dilution into aqueous buffer for assay. Lisuride hydrogen maleate has improved aqueous solubility and can be dissolved directly in acidified water, normal saline, or phosphate-buffered saline for parenteral research applications.

Storage of the solid compound should be at 2 to 8 degrees Celsius in a desiccated container, protected from light. Ergoline derivatives are susceptible to oxidative degradation and epimerization at the C-8 position under light exposure and at elevated temperatures; amber vials and nitrogen atmosphere storage are recommended for long-term stability.

Aqueous solutions should be prepared fresh and used within 24 hours at room temperature, or within 7 to 14 days at 2 to 8 degrees Celsius. DMSO stock solutions are stable for several months at minus 20 degrees Celsius when protected from moisture and light. Aliquoting of stock solutions for single-use is recommended to minimize freeze-thaw cycles, though the compound tolerates at least 3 to 5 freeze-thaw cycles without measurable degradation in DMSO.

For subcutaneous infusion in clinical research, lisuride hydrogen maleate is dissolved in sterile normal saline at concentrations of 0.5 to 2 mg/mL and delivered through a portable infusion pump with a subcutaneous butterfly needle. Infusion solutions should be replaced daily.

10. Stack Interaction Considerations

Lisuride interacts with several drug classes through its multimodal receptor pharmacology and its hepatic metabolism. Investigators conducting research with lisuride, especially in combination protocols, should consider:

Dopamine receptor antagonists: Typical and atypical antipsychotics (haloperidol, risperidone, olanzapine, quetiapine) antagonize the D2 agonist mechanism and reduce or abolish the antiparkinsonian and prolactin-suppressive effects. Concurrent use is pharmacologically contradictory for dopaminergic indications; however, low-dose quetiapine or clozapine may be used to manage lisuride-induced hallucinations in Parkinson's disease patients without abolishing the antiparkinsonian effect.

Levodopa: Lisuride is used clinically as an adjunct to levodopa. The combination is synergistic for antiparkinsonian effect and permits levodopa dose reduction. However, additive dopaminergic adverse events (nausea, orthostatic hypotension, dyskinesia, hallucinations) should be anticipated.

Other dopamine agonists: Concurrent use with bromocriptine, cabergoline, ropinirole, pramipexole, rotigotine, or apomorphine is pharmacologically redundant and increases the risk of dopaminergic adverse events. Switching between agonists requires washout or cross-titration.

Serotonergic agents: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) may have complex interactions with lisuride's serotonergic profile. The 5-HT_{1A} full agonism of lisuride may be additive with SSRI/SNRI-mediated increases in synaptic serotonin, potentially producing serotonergic excess. Monoamine oxidase inhibitors (MAOIs), particularly non-selective MAOIs, are contraindicated owing to the risk of hypertensive crisis and serotonin syndrome.

CYP3A4 inhibitors and inducers: Although the specific CYP isoforms for lisuride metabolism are not fully defined, structural analogy with other ergolines suggests CYP3A4 involvement. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clar-

ithromycin, ritonavir) may increase lisuride exposure. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may reduce lisuride exposure. These interactions have not been formally studied for lisuride.

Antihypertensive agents: Additive hypotensive effects with all antihypertensive classes, particularly alpha-1 blockers (pharmacologically additive with lisuride's alpha-1 antagonism). Orthostatic hypotension monitoring is appropriate.

Antiemetics: Domperidone (a peripheral D2 antagonist that does not cross the blood-brain barrier) is commonly co-prescribed with lisuride to manage dopamine agonist-induced nausea without compromising central antiparkinsonian effect. Metoclopramide (a central and peripheral D2 antagonist) should be avoided as it can reduce antiparkinsonian efficacy.

11. Adverse Events and Safety

11.1 Common adverse events

The principal adverse events of lisuride at clinical doses are consistent with the dopamine agonist class:

- Nausea and vomiting (15 to 25 percent at antiparkinsonian doses; reflects stimulation of D2 receptors in the area postrema; typically managed with domperidone and with dose titration)
- Orthostatic hypotension (10 to 15 percent; reflects alpha-1 adrenergic antagonism and peripheral vasodilation)
- Dizziness (10 to 15 percent)
- Headache (5 to 10 percent)
- Fatigue and somnolence (5 to 10 percent)
- Gastrointestinal disturbances including abdominal pain and diarrhea (5 to 10 percent)
- Nasal congestion (2 to 5 percent)

11.2 Psychiatric adverse events

Psychiatric adverse events are the principal dose-limiting toxicity, particularly in elderly Parkinson's disease patients and at higher doses:

- Hallucinations (visual more common than auditory; 5 to 15 percent at antiparkinsonian doses, higher in elderly and in advanced disease)
- Confusion and disorientation (5 to 10 percent)
- Insomnia and sleep disturbance (5 to 10 percent)
- Paranoid ideation (rare at standard doses; reported in subcutaneous infusion protocols at higher total daily doses) [21]

These psychiatric effects are class effects of dopamine agonists and reflect D2 and D3 receptor stimulation in mesolimbic and mesocortical pathways. They are managed by dose reduction, and in Parkinson's disease patients by the addition of low-

dose clozapine or quetiapine.

11.3 Cardiac valvulopathy risk

The cardiac fibrosis risk is the most clinically significant safety differentiator between lisuride and the ergoline agonists pergolide and cabergoline. Pergolide was withdrawn from the United States market in 2007 following echocardiographic evidence of restrictive valvular disease in a significant proportion of treated patients; the mechanism was identified as 5-HT_{2B} receptor agonism on cardiac valvular interstitial cells, driving myofibroblast proliferation and extracellular matrix deposition. Cabergoline carries regulatory warnings for the same mechanism.

Lisuride is a 5-HT_{2B} receptor antagonist, not an agonist, at this receptor [1]. Hofmann et al. (2006) analyzed adverse drug reaction databases and confirmed the absence of cardiac valvulopathy reports for lisuride, supporting the conclusion that 5-HT_{2B} agonism, not ergoline structure per se, is the molecular determinant of fibrotic risk [1]. The European Medicines Agency review of ergot-derived dopamine agonists in 2008 noted that there was insufficient evidence to determine whether lisuride carried an increased risk of cardiac valve fibrosis, but recommended monitoring for this adverse event as a precautionary measure.

The current evidence supports the conclusion that lisuride does not carry the cardiac valvulopathy risk of pergolide and cabergoline, though periodic echocardiographic monitoring remains advisable for patients on long-term therapy as a class precaution.

11.4 Other safety considerations

Impulse control disorders: Pathological gambling, hypersexuality, compulsive shopping, and binge eating have been reported as class effects of dopamine agonists. Specific data for lisuride are limited, but the risk should be considered equivalent to other D₂/D₃ agonists.

Retroperitoneal and pleuropulmonary fibrosis: Reported with some ergolines (methysergide, ergotamine) on chronic use. Lisuride has not been associated with this complication in published clinical series, consistent with the absence of 5-HT_{2B} agonism.

Prolactin suppression: Therapeutically useful for hyperprolactinemia but contraindicated in patients desiring pregnancy maintenance, as prolactin supports lactation and corpus luteum function.

11.5 Pregnancy and lactation

Lisuride suppresses prolactin secretion and is contraindicated in patients desiring maintenance of pregnancy beyond the first trimester, unless the indication (e.g., prolactin-secreting macroadenoma with chiasmal compression) outweighs the risk. Teratogenicity data in humans are limited; animal studies have not demonstrated teratogenicity at therapeutic dose multiples. The compound passes into breast milk and suppresses lactation; use during breastfeeding is contraindicated.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five dopamine agonist candidates against lisuride, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected as the principal dopamine agonists with substantial clinical evidence in overlapping indications (Parkinson's disease, hyperprolactinemia), representing both the ergoline and non-ergoline subclasses.

12.1 Bromocriptine

Mechanism: Ergoline-class dopamine D2 receptor agonist with partial D1 agonist activity and peripheral serotonin antagonism. Lower D2 affinity than lisuride (Ki approximately 5 to 10 nM versus sub-nanomolar for lisuride).

Development trajectory: Synthesized at Sandoz (now Novartis) in the 1960s, bromocriptine was the first dopamine agonist introduced for clinical use, receiving approval for Parkinson's disease, hyperprolactinemia, and acromegaly beginning in the early 1970s. It remains available globally and is also approved for type 2 diabetes (Cycloset formulation) in the United States [22].

Novelty: Low. Bromocriptine is the oldest and most established ergoline dopamine agonist.

Effect size: Moderate in Parkinson's disease; effective as adjunctive therapy to levodopa for reducing motor fluctuations. Efficacy for prolactin suppression is well established. Direct comparison with lisuride in one small crossover trial showed no significant difference in antiparkinsonian efficacy [9, 20].

Promising potential: Low for new indications. The compound is mature and in generic competition; no novel clinical development is ongoing.

Side-effect profile: Common adverse events include nausea, orthostatic hypotension, and confusion, similar to lisuride. Bromocriptine has been associated with rare cases of pleuropulmonary and retroperitoneal fibrosis on chronic use, and carries a low but non-zero cardiac valvulopathy signal in pharmacovigilance data (less than pergolide or cabergoline but higher than lisuride). Tolerability is generally considered inferior to the non-ergoline agonists.

Overall validation: High. Bromocriptine has the longest clinical history and broadest regulatory approval base of any dopamine agonist.

Comparison to lisuride: Lisuride has higher D2 receptor affinity, broader receptor polypharmacology, and a cleaner cardiac safety profile (5-HT2B antagonism versus modest 5-HT2B agonism for bromocriptine). Bromocriptine has broader regulatory approvals and a larger clinical evidence base. Both compounds share the limitation of multiple daily dosing owing to relatively short half-lives.

12.2 Pergolide

Mechanism: Ergoline-class dopamine D1/D2/D3 receptor agonist. Distinguished from lisuride and bromocriptine by potent D1 agonist activity in addition to D2/D3 agonism.

Development trajectory: Developed by Eli Lilly (marketed as Permax) and approved by the FDA in 1989 for Parkinson's disease as adjunctive therapy to levodopa. Withdrawn from the United States market in March 2007 following the publication of two landmark studies demonstrating significantly increased rates of restrictive cardiac valvular disease (2 to 4 fold risk increase) in pergolide-treated patients [23, 24].

Novelty: Low. The compound is essentially obsolete as a clinical agent in most jurisdictions.

Effect size: The antiparkinsonian efficacy of pergolide was well established in multiple randomized controlled trials and was broadly comparable to bromocriptine and lisuride.

Promising potential: None. The compound has been withdrawn or restricted in most jurisdictions and is not in active development for any indication.

Side-effect profile: The cardiac valvulopathy signal is the defining safety concern. Pergolide is a potent 5-HT_{2B} receptor agonist, and chronic exposure produces fibrotic thickening of cardiac valves (principally mitral and aortic) detectable by echocardiography in a clinically significant proportion of treated patients. Other adverse events are consistent with the dopamine agonist class.

Overall validation: High historical validation for antiparkinsonian efficacy, but effectively invalidated as a clinical agent by the cardiac safety signal.

Comparison to lisuride: Pergolide illustrates the critical importance of the 5-HT_{2B} receptor functional profile in ergoline safety. Lisuride (5-HT_{2B} antagonist) has no cardiac valvulopathy signal; pergolide (5-HT_{2B} agonist) was withdrawn for this reason. The comparison is the single strongest piece of pharmacological evidence supporting the 5-HT_{2B} hypothesis and lisuride's cardiac safety advantage within the ergoline class.

12.3 Cabergoline

Mechanism: Ergoline-class dopamine D₂ receptor agonist with long duration of action (elimination half-life 63 to 69 hours) and 5-HT_{2B} receptor agonist activity.

Development trajectory: Developed by Pharmacia and Upjohn (now Pfizer), marketed as Dostinex. Approved for hyperprolactinemia (the dominant current indication) and for Parkinson's disease adjunctive therapy in some jurisdictions. Cabergoline's long half-life permits once or twice weekly oral dosing for hyperprolactinemia, a major practical advantage over bromocriptine and lisuride, which require daily or multiple-daily dosing [25].

Novelty: Low to moderate. The long half-life pharmacokinetic profile was a meaningful advance for patient convenience in hyperprolactinemia.

Effect size: High for prolactin suppression, generally considered the most effective medical therapy for prolactinomas. Moderate for Parkinson's disease adjunctive therapy, with evidence from the five-year CABERG study demonstrating reduction of motor complication risk compared to levodopa monotherapy.

Promising potential: Moderate. Cabergoline remains the first-line pharmacotherapy for prolactinomas in most guidelines. The cardiac valvulopathy concern has limited the Parkinson's disease indication; current guidelines recommend echocardiographic monitoring at baseline and periodically during treatment.

Side-effect profile: The cardiac valvulopathy risk is established, though the absolute risk at prolactinoma doses (0.25 to 2 mg weekly) is lower than at the higher doses used for Parkinson's disease (3 to 6 mg daily). At prolactinoma doses, clinical valvulopathy is uncommon; at Parkinson's doses, echocardiographic abnormalities are detected in a significant minority of patients [26]. Other adverse events are consistent with the dopamine agonist class.

Overall validation: High for hyperprolactinemia; moderate for Parkinson's disease with the cardiac safety caveat.

Comparison to lisuride: Cabergoline has the practical advantage of weekly dosing for hyperprolactinemia, superior prolactin suppression efficacy, and more extensive clinical evidence. Lisuride has the cardiac safety advantage (5-HT_{2B} antagonism versus 5-HT_{2B} agonism) and the broader serotonergic pharmacology that supports antimigraine and emerging antidepressant research applications. For the Parkinson's disease indication, lisuride's subcutaneous infusion paradigm provides a continuous-stimulation approach that cabergoline's long oral half-life partially addresses through a different route.

12.4 Ropinirole

Mechanism: Non-ergoline dopamine D₂/D₃ receptor agonist. Selective for D₂ and D₃ receptors without clinically significant serotonergic, adrenergic, or histaminergic activity.

Development trajectory: Developed by SmithKline Beecham (now GlaxoSmithKline), marketed as Requip. FDA-approved for Parkinson's disease (1997) and restless legs syndrome (2005). Extended-release formulation (Requip XL) permits once-daily dosing. One of the two dominant non-ergoline dopamine agonists in current global clinical practice [27].

Novelty: Moderate at introduction. The non-ergoline scaffold eliminated the ergoline-associated fibrotic risks.

Effect size: Well established in Parkinson's disease through multiple large randomized controlled trials. Effective as monotherapy in early Parkinson's disease and as adjunctive therapy in advanced disease. Comparable to levodopa for early Parkinson's disease symptom control, though with higher rates of somnolence and psychiatric adverse events.

Promising potential: High for continued use. Ropinirole is a mature product in generic competition but remains a first-line dopamine agonist in Parkinson's disease and restless legs syndrome guidelines globally.

Side-effect profile: No cardiac valvulopathy risk (non-ergoline). Principal adverse events include somnolence (including sudden-onset sleep episodes), nausea, dizziness, orthostatic hypotension, and impulse control disorders. The sudden-onset sleep episodes reported with ropinirole and pramipexole are a distinctive safety concern for this subclass.

Overall validation: High. Extensive randomized controlled trial evidence, FDA approval, and guideline recommendations.

Comparison to lisuride: Ropinirole has the advantage of a well-characterized safety profile, FDA approval, extended-release once-daily formulation, and extensive Phase 3 evidence. Lisuride has the advantage of broader polypharmacology (5-HT_{1A} agonism for anxiolytic and antidepressant effects, 5-HT_{2A} biased agonism for psychoplastogenic research, antimigraine activity), higher D₂ affinity, and the subcutaneous infusion paradigm for advanced disease. The non-ergoline agonists replaced the ergolines as first-line Parkinson's disease therapy in most guidelines, principally on the basis of the cardiac safety concerns that apply to pergolide and cabergoline but not to lisuride.

12.5 Pramipexole

Mechanism: Non-ergoline dopamine D₂/D₃ receptor agonist with preferential D₃ selectivity (approximately 7-fold selectivity for D₃ over D₂).

Development trajectory: Developed by Boehringer Ingelheim, marketed as Mirapex (United States) and Sifrol (Europe). FDA-approved for Parkinson's disease (1997) and restless legs syndrome (2006). Extended-release formulation (Mirapex ER) permits once-daily dosing [28].

Novelty: Moderate. The D₃-preferring selectivity was a novel pharmacological feature relative to bromocriptine and ropinirole.

Effect size: Well established across multiple large randomized controlled trials. Effective as monotherapy in early Parkinson's disease and as adjunctive therapy in advanced disease. The D₃-preferring profile has been associated with potential antidepressant and anhedonia-reducing effects beyond motor symptom control.

Promising potential: High. Pramipexole remains a first-line dopamine agonist with ongoing clinical use and research interest, particularly for the non-motor symptoms of Parkinson's disease (depression, anhedonia, apathy).

Side-effect profile: Similar to ropinirole: no cardiac valvulopathy, but somnolence, sudden-onset sleep, orthostatic hypotension, nausea, and impulse control disorders. Impulse control disorder prevalence may be higher with pramipexole than with ropinirole in some analyses, potentially related to D3 selectivity.

Overall validation: High. Extensive Phase 3 evidence, FDA approval, and guideline recommendations.

Comparison to lisuride: Pramipexole shares with ropinirole the advantages of non-ergoline safety, FDA approval, and once-daily extended-release formulation. Lisuride has the unique advantages of 5-HT_{1A} full agonism, G protein-biased 5-HT_{2A} partial agonism, 5-HT_{2B} antagonism (cardiac safety within the ergoline class), and the subcutaneous infusion continuous-stimulation paradigm. The D₃-preferring profile of pramipexole may confer antidepressant advantages within the D₂/D₃ agonist mechanism, while lisuride's antidepressant potential operates through the distinct 5-HT_{2A} G protein-biased pathway.

12.6 Comparator summary

The five comparator compounds represent the full spectrum of dopamine agonist pharmacology in clinical use. **Bromocriptine** is the historical reference ergoline with the broadest approval base but inferior tolerability and modest cardiac risk. **Pergolide** demonstrates the consequence of 5-HT_{2B} agonism in an ergoline scaffold and serves as the negative-safety reference against which lisuride's 5-HT_{2B} antagonism is most clearly validated. **Cabergoline** is the current first-line agent for hyperprolactinemia with the advantage of weekly dosing but the disadvantage of cardiac valvulopathy risk at higher Parkinson's disease doses. **Ropinirole** and **pramipexole** are the dominant non-ergoline agonists with extensive Phase 3 evidence and guideline support, but without the multimodal serotonergic pharmacology of lisuride.

Lisuride occupies a unique position in this comparator landscape. It is the only compound with demonstrated 5-HT_{2B} receptor antagonism (conferring cardiac safety within the ergoline class), the only compound with G protein-biased 5-HT_{2A} partial agonism (supporting non-hallucinogenic psychoplastogenic and antidepressant research), the only compound with sub-nanomolar 5-HT_{1A} full agonism (sup-

porting anxiolytic activity), and the only compound with established subcutaneous infusion delivery for continuous dopaminergic stimulation in advanced Parkinson's disease predating the apomorphine pump paradigm. Its principal limitations are the absence of FDA approval, the limited randomized controlled trial evidence for oral antiparkinsonian efficacy, the short half-life requiring multiple daily dosing, and the commercial displacement by non-ergoline agonists in first-line Parkinson's disease guidelines.

The most compelling contemporary research positioning of lisuride is not as a Parkinson's disease agent in competition with ropinirole and pramipexole, but as a pharmacological tool and potential therapeutic agent at the intersection of dopaminergic and serotonergic neuroscience. The G protein-biased 5-HT_{2A} agonism, the 5-HT_{2B} safety profile, the 5-HT_{1A} full agonism, and the established human safety database combine to position lisuride uniquely among known compounds for the investigation of non-hallucinogenic psychoplastogenic antidepressant mechanisms.

13. References

1. Hofmann C, Penner U, Dorow R, et al. Lisuride, a dopamine receptor agonist with 5-HT_{2B} receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT_{2B} receptor agonism in cardiac valvular fibrosis. *Clin Neuropharmacol*. 2006;29(2):80-86.
2. Gonzalez-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT_{2A} receptor-mediated signaling pathways to affect behavior. *Neuron*. 2007;53(3):439-452.
3. Secker C, Brosda J, Koch M, et al. The G protein biased serotonin 5-HT_{2A} receptor agonist lisuride exerts anti-depressant drug-like activities in mice. *Front Mol Biosci*. 2023;10:1233743.
4. Krause W, Jakobs H, Fischer C. Pharmacokinetics and pharmacodynamics of lisuride in healthy volunteers after intravenous, intramuscular, and subcutaneous injection. *Eur J Clin Pharmacol*. 1991;41(6):555-560.
5. Obeso JA, Luquin MR, Martinez-Lage JM. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration. *J Neural Transm Suppl*. 1988;27:143-152.
6. National Institute of Neurological Disorders and Stroke. Lisuride patch to treat Parkinson's disease. *ClinicalTrials.gov* identifier: NCT00089622.
7. Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. *Brain*. 2002;125(Pt 9):2058-2066.
8. LeWitt PA, Gopinathan G, Ward CD, et al. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies. *Neurology*. 1983;33(6):769-772.
9. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. *Neurology*. 1989;39(3):336-339.
10. Zikan V, Semonsky M. Ergolines. I. Lysergic acid derivatives with 8-aminoalkyl substituents. *Collect Czech Chem Commun*. 1960;25:1922-1928.

11. Horowski R, Dorow R, Paschelke G, Amin M, Braun M. Lisuride: an 8- α -ergoline with ergot antagonistic properties. In: Riederer P, et al., eds. *Pharmacology of Parkinson's Disease*. Springer; 1989:287-301.
12. Roth BL, Lopez E, Patel S, Kroeze WK. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? *Neuroscientist*. 2000;6(4):252-262.
13. Ray TS. Psychedelics and the human receptorome. *PLoS One*. 2010;5(2):e9019.
14. Horowski R, Wachtel H. Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. *Eur J Pharmacol*. 1976;36(2):373-383.
15. Horowski R. Pharmacological and behavioral characteristics of lisuride as a dopamine agonist. *Clin Neuropharmacol*. 1985;8(Suppl 1):S10-S20.
16. Liuzzi A, Chiodini PG, Botalla L, et al. Lisuride, a new drug for treatment of hyperprolactinaemic disorders. *Acta Endocrinol (Copenh)*. 1980;95(Suppl 234):94-96.
17. Vance ML, Evans WS, Thorner MO. Lisuride in the treatment of prolactinomas. *Ann Intern Med*. 1984;100(1):78-82.
18. Obeso JA, Luquin MR, Martinez-Lage JM. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. *Lancet*. 1986;1(8479):467-470.
19. Kehler J, Thomsen Lindskov MS. Are the LSD-analogs lisuride and ergotamine examples of non-hallucinogenic serotonin 5-HT_{2A} receptor agonists? *J Psychopharmacol*. 2025;39(3):251-265.
20. van Hilten JJ, Ramaker CC, Stowe RL, Ives NJ. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease. *Cochrane Database Syst Rev*. 2007;(4):CD003634.
21. Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. *Brain*. 1991;114(Pt 1B):601-614.
22. Croom KF, Wellington K. Bromocriptine. In: *Dopamine Agonists in Parkinson's Disease*. Drugs. 2006;66(3):365-380.
23. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. *N Engl J Med*. 2007;356(1):39-46.

24. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. *N Engl J Med*. 2007;356(1):29-38.
 25. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. *N Engl J Med*. 1994;331(14):904-909.
 26. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. *Lancet Neurol*. 2007;6(9):826-829.
 27. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. *Neurology*. 1997;49(2):393-399.
 28. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. *Neurology*. 1997;49(3):724-728.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Lisuride is not approved by the United States Food and Drug Administration. The compound is registered as a medicine in several European and other jurisdictions; investigators should consult their local regulatory authority before any human research application.